Tarius SAC Tracker®

 

Results Wire: US FDA Advisory Committee Does Not Support Fabre-Kramer Pharmaceuticals’ Gepirone ER for Major Depressive Disorder – DEC 1, 2015 (PDAC)

The SAC Tracker report for this meeting is only available for SAC Tracker Premium subscribers.

The SAC Tracker reports are available for FREE on this site until 10 days after the meeting is held. 

To obtain unlimited access to SAC Tracker meeting reports back to 2010 and onwards, including the committee members' voting history, you must subscribe to the SAC Tracker Premium service.

Read more and subscribe here.


METADATA: Sponsor: Fabre-Kramer Pharmaceuticals, Inc. Drug Name: gepirone ER Drug Class: 5-HT1A receptor agonist Indication: major depressive disorder